Vertex Pharmaceuticals (VRTX) Gains from Investment Securities (2015 - 2024)
Vertex Pharmaceuticals' (VRTX) quarterly Gains from Investment Securities came in at -$1.2 million in Q4 2024, up 97.61% year-on-year from -$607243.5 in Q1 2024, and down 500.0% quarter-over-quarter from $300000.0 in Q3 2024.
Vertex Pharmaceuticals (VRTX) Gains from Investment Securities (2015 - 2024) Analysis & Trends
Vertex Pharmaceuticals' Gains from Investment Securities history runs 9 years deep, the most recent figure standing at -$1.2 million for Q4 2024.
- On a quarterly basis, Gains from Investment Securities rose 97.61% year-over-year to -$1.2 million in Q4 2024; TTM through Dec 2024 was -$500000.0, a 99.03% increase from a year earlier, with the FY2024 full-year figure at -$500000.0, up 99.03% from the prior year.
- Gains from Investment Securities fell to -$1.2 million in Q4 2024 per VRTX's latest filing, from $300000.0 in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $9.2 million in Q2 2020 and bottomed at -$50.3 million in Q4 2023.
- The 5-year median for Gains from Investment Securities is $100000.0 (2024), against an average of -$5.0 million.
- Biggest YoY gain for Gains from Investment Securities was 190.0% in 2022; the steepest drop was 3175.0% in 2022.
- Year by year, Gains from Investment Securities stood at $500000.0 in 2020, then slumped by 500.0% to -$2.0 million in 2021, then soared by 190.0% to $1.8 million in 2022, then slumped by 2894.44% to -$50.3 million in 2023, then surged by 97.61% to -$1.2 million in 2024.
- Per Business Quant, the three latest VRTX Gains from Investment Securities figures stand at -$1.2 million (Q4 2024), $300000.0 (Q3 2024), and $500000.0 (Q2 2024).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -1.20 Mn |
| Dec 31, 2024 | -1.20 Mn |
| Sep 30, 2024 | 300,000.00 |
| Sep 30, 2024 | 300,000.00 |
| Jun 30, 2024 | 500,000.00 |
| Jun 30, 2024 | 500,000.00 |
| Mar 31, 2024 | -100,000.00 |
| Mar 31, 2024 | -100,000.00 |
| Dec 31, 2023 | -50.30 Mn |
| Dec 31, 2023 | -50.30 Mn |
| Sep 30, 2023 | 1.20 Mn |
| Sep 30, 2023 | 1.20 Mn |
| Jun 30, 2023 | -600,000.00 |
| Jun 30, 2023 | -600,000.00 |
| Mar 31, 2023 | -1.90 Mn |
| Mar 31, 2023 | -1.90 Mn |
| Dec 31, 2022 | 1.80 Mn |
| Dec 31, 2022 | 1.80 Mn |
| Sep 30, 2022 | -2.60 Mn |
| Sep 30, 2022 | -2.60 Mn |